Gilead Sciences Analyst Ratings
RBC Capital Reiterates Sector Perform on Gilead Sciences, Maintains $74 Price Target
Gilead Sciences (GILD) Receives a Hold From RBC Capital
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $119 From $117
Gilead Sciences Analyst Ratings
Baird Maintains Neutral on Gilead Sciences, Maintains $80 Price Target
What 8 Analyst Ratings Have To Say About Gilead Sciences
RBC Capital Reiterates Sector Perform on Gilead Sciences, Maintains $74 Price Target
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Gilead Sciences (GILD) and Sanofi (OtherSNYNF)
Hold Rating on Gilead Sciences Amid Trodelvy Trial Setbacks and Future Uncertainties
Analysts' Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD), Biogen (BIIB) and Argenx Se (ARGX)
Analysts' Top Healthcare Picks: Scholar Rock Holding (SRRK), Gilead Sciences (GILD)
Gilead Sciences (GILD) Gets a Hold From Wells Fargo
UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating
Analysts' Top Healthcare Picks: Bio-Techne (TECH), Gilead Sciences (GILD)
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $117 From $120
Analysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences (GILD) and Omega Therapeutics (OMGA)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (TDOC), R1 RCM (RCM) and Gilead Sciences (GILD)
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Gilead Sciences (GILD) and Sanofi (OtherSNYNF)
Barclays: Maintaining the Gilead Sciences (GILD.US) rating, adjusted from a shareholding wait-and-see rating to a shareholding wait-and-see rating, and the target price was adjusted from $80.00 to $76.00.